Folate pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children

Sirachainan, Nongnuch; Wongruangsri, Siranee; Kajanachumpol, Saowanee; Pakakasama, Samart; Visudtibhan, Anannit; Nuchprayoon, Issarang; Lusawat, Apasri; Phudhicharoenrat, Suchart; Shuangshoti, Shanop; Hongeng, Suradej

doi:10.1016/j.cdp.2008.02.004

Cited by 35 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Thai study investigated MTHFR 677C>T and 1298A>C, MTR 2756A>G, thymidylate synthase (TS) 28 bp tandem repeat and reduced folate carrier (RFC) 80GA. Similar to our findings, these investigators reported no significant association overall between the child's MTHFR 677C>T, MTHFR 1298A>C or MTR 2756A>G genotype and risk of CBT (6). This study reported an increased risk of embryonal tumors associated with the MTHFR 1298CC genotype (OR 3.9; 95% CI, 1.3-11.4); the corresponding OR in our study was 1.66 (95% CI, 0.66-4.14), based on 7 cases and 42 controls.…”

Section: Discussionsupporting

confidence: 81%

“…A Thai case-control study investigated five folate pathway polymorphisms in 73 case and 205 control children and reported an increased risk of embryonal tumors (n ¼ 28) associated with the MTHFR 1298CC genotype (6). This study also reported elevated associations between the MTHFR 677CT/TT and MTR 2756AG genotype and risk of glial tumors (n ¼ 31); however, this association was not statistically significant.…”

Section: Introductionmentioning

confidence: 64%

“…Two previous studies have investigated folate pathway polymorphisms in relation to CBT risk (6,7). A Thai case-control study investigated five folate pathway polymorphisms in 73 case and 205 control children and reported an increased risk of embryonal tumors (n ¼ 28) associated with the MTHFR 1298CC genotype (6).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Folate Pathway Gene Polymorphisms and Risk of Childhood Brain Tumors: Results from an Australian Case–Control Study

Greenop¹,

Scott²,

Attia³

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Recent research suggests that maternal folic acid supplementation is associated with a reduced risk of childhood brain tumors (CBT); polymorphisms in folate pathway genes could modify this association or directly influence CBT risk.Methods: Associations between risk of CBT and folate pathway polymorphisms were investigated in a population-based casecontrol study in Australia (2005Australia ( -2010. Cases were recruited through all Australian pediatric oncology centers and controls by national random digit dialing. Data were available from 321 cases and 552 controls. Six polymorphisms were genotyped in children and parents (MTHFR 677C>T, MTHFR 1298A>C, MTRR 66A>G, MTR 2756A>G, MTR 5049C>A, and CBS 2199 T>C). Maternal folic acid use was ascertained via questionnaire. ORs were estimated using unconditional logistic regression. Caseparent trio analyses were also undertaken.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 64%

See 1 more Smart Citation

Folate Pathway Gene Polymorphisms and Risk of Childhood Brain Tumors: Results from an Australian Case–Control Study

Greenop¹,

Scott²,

Attia³

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…We were notified of 794 CBT cases, of which 64 were ineligible (36 (17). In accordance with our frequency-matching quotas, 1,467 of these families were recruited to the study.…”

Section: Resultsmentioning

confidence: 99%

Maternal Use of Folic Acid and Other Supplements and Risk of Childhood Brain Tumors

Milne

Greenop

Bower

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Interest in a possible protective effect of maternal vitamin use before or during pregnancy against childhood brain tumors (CBT) and other childhood cancers has grown over the past decade. Our Australian study of CBTs, conducted between 2005 and 2011, investigated whether maternal use folic acid and other supplements was protective.Methods: Case children were identified through the 10 Australian pediatric oncology centers and controls were recruited by national random digit dialing. Mothers of 327 cases and 867 control children provided information on supplement use before and during the index pregnancy, including brand name, dose, and timing. Data were analyzed using multivariable unconditional logistic regression.Results: The OR for any maternal use of folic acid, use of folic acid without iron or vitamins B6, B12, C, or A, and any vitamin use before pregnancy, were: 0.68 [95% confidence interval (CI), 0.46-1.00; 0.55 (95% CI, 0.32-0.93) and 0.68 (95% CI, 0.46-1.01), respectively. The ORs for use of these supplements during pregnancy were also below unity, but generally closer to the null than those for the prepregnancy period. There was some evidence of an inverse dose-response during each time period.Conclusions: These results suggest that folic acid supplements before and possibly during pregnancy may protect against CBT. Such associations are biologically plausible through established mechanisms.Impact: This study provides evidence of a specific protective effect of prenatal folic acid supplementation against the risk of CBT that is not attributable to the actions of the other micronutrients investigated. Cancer Epidemiol Biomarkers Prev; 21(11); 1933-41. Ó2012 AACR.

show abstract

“…In a previous Brazilian series, MTHFR A1298C polymorphism was associated with an increased risk of acute lymphoblastic leukemia and acute myelogenous leukemia in nonwhite children (da Costa Ramos et al, 2006;Zanrosso et al, 2006). In embryonic solid childhood tumors, several data have suggested an association of MTHFR C677T with nephroblastoma, MTHFR A1298C with embryonic central nervous system tumors, and MTR (methionine synthase) A2756G with retinoblastoma (Sirachainan et al, 2008;Ferrara et al, 2009;De Lima et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

RFC-180G>A Polymorphism in Case-Mother/Control-Mother Dyads Is Associated with Risk of Nephroblastoma and Neuroblastoma

Azevedo

VasconcelosGisele

VargasFernando

et al. 2015

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Aim: Embryonic tumors are associated with an interruption during normal organ development; they may be related to disturbances in the folate pathway involved in DNA synthesis, methylation, and repair. Prenatal supplementation with folic acid is associated with a decreased risk of neuroblastoma, brain tumors, retinoblastoma, and nephroblastoma. The aim of this study was to investigate the association between MTHFR rs1801133 (C677T) and RFC-1 rs1051266 (G80A) genotypes with the risk of developing nephroblastoma and neuroblastoma. Materials and Methods: Case-mother/control-mother dyad study. Samples from Brazilian children with nephroblastoma (n = 80), neuroblastoma (n = 66), healthy controls (n = 453), and their mothers (case n = 93; control n = 75) were analyzed. Genomic DNA was isolated from peripheral blood cells and/or buccal cells and genotyped to identify MTHFR C677T and RFC-1 G80A polymorphisms. Differences in genotype distribution between patients and controls were tested by multiple logistic regression analysis. Results: Risk for nephroblastoma and neuroblastoma was two-to fourfold increased among children with RFC-1 polymorphisms. An increased four-to eightfold risk for neuroblastoma and nephroblastoma was seen when the child and maternal genotypes were combined. Conclusion: Our results suggest that mother and child RFC-1 G80A genotypes play a role on the risk of neuroblastoma and nephroblastoma since this polymorphism may impair the intracellular levels of folate, through carrying fewer folate molecules to the cell interior, and thus, the intracellular concentration is not enough to maintain regular DNA synthesis and methylation pathways.

show abstract

Folate pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children

Cited by 35 publications

References 39 publications

Folate Pathway Gene Polymorphisms and Risk of Childhood Brain Tumors: Results from an Australian Case–Control Study

Folate Pathway Gene Polymorphisms and Risk of Childhood Brain Tumors: Results from an Australian Case–Control Study

Maternal Use of Folic Acid and Other Supplements and Risk of Childhood Brain Tumors

RFC-180G>A Polymorphism in Case-Mother/Control-Mother Dyads Is Associated with Risk of Nephroblastoma and Neuroblastoma

Contact Info

Product

Resources

About